Izotropic Corporation has announced promising scientific research results related to its IzoView Breast CT Imaging System. The findings highlight IzoView's potential to revolutionize breast cancer imaging by offering true 3D imaging without the need for breast compression, effectively bridging the gap between digital breast tomosynthesis (DBT) and magnetic resonance imaging $(MRI.AU)$. IzoView is designed to integrate seamlessly into various healthcare environments and aims to provide a more accurate and patient-friendly alternative to existing imaging technologies. These results will be presented in future scientific forums, as the company continues to demonstrate IzoView's capabilities and clinical advantages.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。